Drug Evaluation

Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma

Sarah Chehab

Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA

Search for more papers by this author

Elyse Hall Panjic

Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA

Search for more papers by this author

Charise Gleason

Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA

Search for more papers by this author

Sagar Lonial

Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA

Search for more papers by this author

Ajay K Nooka

*Author for correspondence: Tel.: +1 404 778 0659; Fax: +1 404 778 5530;

E-mail Address: anooka@emory.edu

Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA

Search for more papers by this author

Published Online:23 Aug 2018https://doi.org/10.2217/fon-2018-0275

View article

Abstract

Daratumumab gained initial US FDA approval as fourth-line therapy among relapsed and/or refractory multiple myeloma (RRMM) patients who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and immunomodulatory drug (IMiD), or who are double refractory to a PI and an IMiD. Further combination trials of daratumumab led to FDA approvals in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone for multiple myeloma patients who have received at least one prior therapy. The most recent expansion of the FDA approval of daratumumab comes in combination with pomalidomide and dexamethasone for patients with multiple myeloma that have received ≥2 prior lines of therapy including lenalidomide and a PI. The current manuscript reviews data supporting the efficacy and safety of daratumumab in RRMM.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1 NIH. Cancer Stat Facts: Myeloma (2018). https://seer.cancer.gov/statfacts/html/mulmy.html.Google Scholar
2 Kumar SK, Lee JH, Lahuerta JJ et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26(1), 149–157 (2012).Crossref, Medline, CAS, Google Scholar
3 Kumar SK, Dimopoulos MA, Kastritis E et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 31(11), 2443–2448 (2017).Crossref, Medline, CAS, Google Scholar
4 Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K. Human CD38: a glycoprotein in search of a function. Immunol. Today 15(3), 95–97 (1994).Crossref, Medline, CAS, Google Scholar
5 Malavasi F, Deaglio S, Funaro A et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol. Rev. 88(3), 841–886 (2008).Crossref, Medline, CAS, Google Scholar
6 Deaglio S, Morra M, Mallone R et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J. Immunol. 160(1), 395–402 (1998).Medline, CAS, Google Scholar
7 Ausiello CM, la Sala A, Ramoni C, Urbani F, Funaro A, Malavasi F. Secretion of IFN-gamma, IL–6, granulocyte-macrophage colony-stimulating factor and IL-10 cytokines after activation of human purified T lymphocytes upon CD38 ligation. Cell. Immunol. 173(2), 192–197 (1996).Crossref, Medline, CAS, Google Scholar
8 Dianzani U, Funaro A, DiFranco D et al. Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule. J. Immunol. 153(3), 952–959 (1994).Medline, CAS, Google Scholar
9 Funaro A, De Monte LB, Dianzani U, Forni M, Malavasi F. Human CD38 is associated to distinct molecules which mediate transmembrane signaling in different lineages. Eur. J. Immunol. 23(10), 2407–2411 (1993).Crossref, Medline, CAS, Google Scholar
10 Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am. J. Clin. Pathol. 121(4), 482–488 (2004).Crossref, Medline, Google Scholar
11 Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk. Res. 25(1), 1–12 (2001).Crossref, Medline, CAS, Google Scholar
12 de Weers M, Tai YT, van der Veer MS et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186(3), 1840–1848 (2011).Crossref, Medline, CAS, Google Scholar
13 Overdijk MB, Verploegen S, Bogels M et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs 7(2), 311–321 (2015).Crossref, Medline, CAS, Google Scholar
14 Krejcik J, Casneuf T, Nijhof IS et al. Daratumumab depletes CD38⁺ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128(3), 384–394 (2016).Crossref, Medline, CAS, Google Scholar
15 Lokhorst HM, Plesner T, Laubach JP et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373(13), 1207–1219 (2015).Crossref, Medline, CAS, Google Scholar
16 Lonial S, Weiss BM, Usmani SZ et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, Phase II trial. Lancet 387(10027), 1551–1560. • Highest response rates as a single agent in heavily pretreated patients relative to all other approved antimyeloma agents.Crossref, Medline, Google Scholar
17 Plesner T, Arkenau H-T, Gimsing P et al. Phase I/II study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood 128(14), 1821–1828 (2016).Crossref, Medline, CAS, Google Scholar
18 Chari A, Suvannasankha A, Fay JW et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 130(8), 974–981 (2017). • Phase II trial of daratumumab in combination with pomalidomide and dexamethasone gaining the US FDA approval of this combination.Crossref, Medline, CAS, Google Scholar
19 Facon T, Lonial S, Weiss BM et al. Daratumumab in combination with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma (RRMM) patients with ≥2 prior lines of therapy: updated analysis of MMY1001. Blood 130(Suppl. 1), 1824 (2017).Google Scholar
20 Lonial S, San-Miguel JF, Martínez-Lopez J et al. Daratumumab in combination with carfilzomib and dexamethasone in patients (pts) with relapsed multiple myeloma (MMY1001): an open-label, Phase Ib study. Blood 130(Suppl. 1), 1869 (2017). • Phase II trial demonstrating the safety and efficacy of daratumumab in combination with carfilzomib and dexamethasone.Medline, Google Scholar
21 Nooka AK, Joseph N, Boise LH, Gleason C, Kaufman JL, Lonial S. Clinical efficacy of daratumumab, pomalidomide and dexamethasone in relapsed, refractory myeloma patients: utility of retreatment with daratumumab among refractory patients. Blood 128(22), 492 (2016). • First study to show the utility of retreatment with daratumumab in myeloma patients refractory to daratumumab.Crossref, Google Scholar
22 Spencer A, Hungria VTM, Mateos M-V et al. Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of castor. Blood 130(Suppl. 1), 3145 (2017).Google Scholar
23 Palumbo A, Chanan-Khan A, Weisel K et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375(8), 754–766 (2016). • Phase III trial showing superiority of daratumumab in combination with bortezomib and dexamethasone to bortezomib and dexamethasone.Crossref, Medline, CAS, Google Scholar
24 Dimopoulos MA, White DJ, Benboubker L et al. Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of pollux. Blood 130(Suppl. 1), 739 (2017).Crossref, Google Scholar
25 Dimopoulos MA, Oriol A, Nahi H et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375(14), 1319–1331 (2016). • Phase III trial showing superiority of daratumumab in combination with bortezomib and dexamethasone to bortezomib and dexamethasone.Crossref, Medline, CAS, Google Scholar
26 Usmani SZ, Weiss BM, Plesner T et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood 128(1), 37–44 (2016).Crossref, Medline, CAS, Google Scholar
27 Mateos M-V, Spencer A, Nooka AK et al. Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): subgroup analysis of POLLUX and CASTOR. J. Clin. Oncol. 35(Suppl. 15), 8033 (2017). • Subgroup anlaysis of Phase III trial demonstrating the safety and efficacy of daratumumab in combination with bortezomib or lenalidomide and dexamethasone among elderly patients.Crossref, Google Scholar
28 Mateos M-V, Estell J, Barreto W et al. Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of castor. Blood 128(22), 1150 (2016).Crossref, Google Scholar
29 Usmani SZ, Dimopoulos MA, Belch A et al. Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: updated analysis of pollux. Blood 128(22), 1151 (2016).Crossref, Google Scholar
30 DARZALEX^® (Daratumumab). www.janssenmd.com/pdf/darzalex/darzalex_pi.pdf.Google Scholar
31 Chari A, Mark TM, Krishnan A et al. Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States Patients with Relapsed or refractory multiple myeloma. Blood 128(22), 2142 (2016).Crossref, Google Scholar
32 Chari A, Nahi H, Mateos M-V et al. Subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (RRMM): pavo, an open-label, multicenter, dose escalation Phase Ib study. Blood 130(Suppl. 1), 838 (2017). • Phase I trial demonstrating the safety and efficacy of subcutaneous administration of daratumumab in myeloma patients.Crossref, Google Scholar
33 Sullivan HC, Gerner-Smidt C, Nooka AK et al. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood 129(22), 3033–3037 (2017).Crossref, Medline, CAS, Google Scholar
34 Chapuy CI, Nicholson RT, Aguad MD et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion 55(6 Pt 2), 1545–1554 (2015).Crossref, Medline, CAS, Google Scholar
35 Chari A, Satta T, Tayal A et al. Outcomes and management of red blood cell transfusions in multiple myeloma patients treated with daratumumab. Blood 126(23), 3571 (2015).Crossref, Google Scholar

Vol. 14, No. 30

Metrics

Downloaded 284 times

History

Received 5 April 2018

Accepted 29 June 2018

Published online 23 August 2018

Published in print December 2018

Information

Keywords

Financial & competing interests disclosure

S Chehab, EH Panjic and C Gleason have nothing to disclose. S Lonial served on an Advisory Board for Janssen. AK Nooka has consulted for Janssen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download